Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies

Melissa L. Johnson; Marina Chiara Garassino; Tony Mok; Tetsuya Mitsudomi

doi:10.1016/j.lungcan.2022.05.011

Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies

Authors: Melissa L. Johnson, Marina Chiara Garassino, Tony Mok, Tetsuya Mitsudomi - Lung Cancer 2022 cited by 150

Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies | Litlas